Analysis by multicolor immunofluorescence and immunohistochemistry revealed that rPR8-CCL19 remodeled the tumor TME, characterized by the robust recruitment and activation of both CD4+ and CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.